These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7635999)

  • 1. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia.
    Arthur H; Dahl ML; Siwers B; Sjöqvist F
    J Clin Psychopharmacol; 1995 Jun; 15(3):211-6. PubMed ID: 7635999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics.
    Ohmori O; Suzuki T; Kojima H; Shinkai T; Terao T; Mita T; Abe K
    Schizophr Res; 1998 Jul; 32(2):107-13. PubMed ID: 9713906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.
    Kapitany T; Meszaros K; Lenzinger E; Schindler SD; Barnas C; Fuchs K; Sieghart W; Aschauer HN; Kasper S
    Schizophr Res; 1998 Jul; 32(2):101-6. PubMed ID: 9713905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype.
    Jaanson P; Marandi T; Kiivet RA; Vasar V; Vään S; Svensson JO; Dahl ML
    Psychopharmacology (Berl); 2002 Jun; 162(1):67-73. PubMed ID: 12107620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients.
    Andreassen OA; MacEwan T; Gulbrandsen AK; McCreadie RG; Steen VM
    Psychopharmacology (Berl); 1997 May; 131(2):174-9. PubMed ID: 9201806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients.
    Liou YJ; Wang YC; Bai YM; Lin CC; Yu SC; Liao DL; Lin MW; Chen JY; Lai IC
    Neuropsychobiology; 2004; 49(4):167-73. PubMed ID: 15118351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
    Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
    Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
    J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.
    Scordo MG; Spina E; Romeo P; Dahl ML; Bertilsson L; Johansson I; Sjöqvist F
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):679-83. PubMed ID: 11214775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6.
    Ellingrod VL; Schultz SK; Arndt S
    Pharmacotherapy; 2002 Nov; 22(11):1416-9. PubMed ID: 12432967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
    Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
    Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
    Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
    Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score.
    Ellingrod VL; Schultz SK; Arndt S
    Psychiatr Genet; 2000 Mar; 10(1):9-11. PubMed ID: 10909122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
    Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
    Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
    Sandwall P; Lo MW; Jonzon B; Dalén P; Furtek C; Ritter M; Alván G; McCrea J; Sjöqvist F
    Eur J Clin Pharmacol; 1999 Jun; 55(4):279-83. PubMed ID: 10424320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.
    Inada T; Senoo H; Iijima Y; Yamauchi T; Yagi G
    Psychiatr Genet; 2003 Sep; 13(3):163-8. PubMed ID: 12960748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects.
    Ivanova SA; Filipenko ML; Vyalova NM; Voronina EN; Pozhidaev IV; Osmanova DZ; Ivanov MV; Fedorenko OY; Semke AV; Bokhan NA
    Bull Exp Biol Med; 2016 Mar; 160(5):687-90. PubMed ID: 27021090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.